The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers\' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.
Epistemonikos ID: db198522df08a44f34e22f74262d095e7cc8b4d2
First added on: May 12, 2024